AU2008274956B2 - Inhibitors of Akt/PKB with anti-tumor activity - Google Patents

Inhibitors of Akt/PKB with anti-tumor activity Download PDF

Info

Publication number
AU2008274956B2
AU2008274956B2 AU2008274956A AU2008274956A AU2008274956B2 AU 2008274956 B2 AU2008274956 B2 AU 2008274956B2 AU 2008274956 A AU2008274956 A AU 2008274956A AU 2008274956 A AU2008274956 A AU 2008274956A AU 2008274956 B2 AU2008274956 B2 AU 2008274956B2
Authority
AU
Australia
Prior art keywords
cell
akt
alkyl
compound
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008274956A
Other languages
English (en)
Other versions
AU2008274956A1 (en
Inventor
Jin Q. Cheng
Said M. Sebti
Mei Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida St. Petersburg
Original Assignee
University of South Florida
University of South Florida St. Petersburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida, University of South Florida St. Petersburg filed Critical University of South Florida
Publication of AU2008274956A1 publication Critical patent/AU2008274956A1/en
Application granted granted Critical
Publication of AU2008274956B2 publication Critical patent/AU2008274956B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2008274956A 2007-07-12 2008-07-14 Inhibitors of Akt/PKB with anti-tumor activity Ceased AU2008274956B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94936507P 2007-07-12 2007-07-12
US60/949,365 2007-07-12
PCT/US2008/069974 WO2009009793A2 (en) 2007-07-12 2008-07-14 Inhibitors of akt/pkb with anti-tumor activity

Publications (2)

Publication Number Publication Date
AU2008274956A1 AU2008274956A1 (en) 2009-01-15
AU2008274956B2 true AU2008274956B2 (en) 2014-08-21

Family

ID=40229514

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008274956A Ceased AU2008274956B2 (en) 2007-07-12 2008-07-14 Inhibitors of Akt/PKB with anti-tumor activity

Country Status (10)

Country Link
US (2) US8183249B2 (cg-RX-API-DMAC10.html)
EP (1) EP2173352B1 (cg-RX-API-DMAC10.html)
JP (1) JP5568471B2 (cg-RX-API-DMAC10.html)
KR (1) KR101618037B1 (cg-RX-API-DMAC10.html)
CN (1) CN101743007B (cg-RX-API-DMAC10.html)
AU (1) AU2008274956B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0815563A2 (cg-RX-API-DMAC10.html)
CA (1) CA2695330C (cg-RX-API-DMAC10.html)
MX (1) MX2010000474A (cg-RX-API-DMAC10.html)
WO (1) WO2009009793A2 (cg-RX-API-DMAC10.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101229647B1 (ko) * 2004-09-03 2013-02-05 메르크 세로노 에스.에이. 피리딘 메틸렌 아조리디논 및 포스포이노시타이드 저해제의용도
CN101743007B (zh) * 2007-07-12 2015-04-08 南佛罗里达大学 具有抗肿瘤活性的akt/pkb抑制剂
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド ジケトピペラジンを用いた医薬組成物
EP2613786A4 (en) 2010-09-07 2013-10-23 Dmi Acquisition Corp TREATMENT OF DISEASES
WO2012158197A2 (en) * 2010-11-11 2012-11-22 Lyndor Biosciences L.L.C. Compounds useful as akt/pkb modulators and uses thereof
SG194050A1 (en) * 2011-04-01 2013-11-29 Genentech Inc Biomarkers for predicting sensitivity to cancer treatments
FI2694072T4 (fi) 2011-04-01 2024-09-30 Genentech Inc Akt-inhibiittoriyhdisteen ja abirateronin yhdistelmä käytettäväksi terapeuttisissa hoidoissa
CN102225067B (zh) * 2011-04-29 2012-10-03 济南环肽医药科技有限公司 一种治疗胃癌的药物组合物
JP2014530063A (ja) 2011-10-10 2014-11-17 アンピオ ファーマシューティカルズ，インコーポレイテッド 免疫寛容が高められた埋込み型医療用デバイス、ならびに製造方法および埋込み方法
PH12014500685B1 (en) 2011-10-10 2018-10-03 Ampio Pharmaceuticals Inc Treatment of degenerative joint disease
HK1198812A1 (en) 2011-10-28 2015-06-12 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
GB201207722D0 (en) * 2012-05-02 2012-06-13 Bergenbio As Method
KR101461626B1 (ko) * 2012-08-02 2014-11-28 서울대학교산학협력단 Ａｋｔ１ 억제제 및 소수성 항암제를 포함하는 항암용 약학적 조성물
WO2014074883A1 (en) * 2012-11-08 2014-05-15 Lyndor Biosciences L.L.C. Novel synthesis of ld101
CA2906864A1 (en) 2013-03-15 2014-09-18 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
AU2014293013A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Combinatorial methods to improve the therapeutic benefit of bisantrene
US9986375B2 (en) * 2014-02-12 2018-05-29 Google Llc Energy-efficient location determination
EP4066836A1 (en) 2014-08-18 2022-10-05 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
FR3033499A1 (fr) * 2015-03-11 2016-09-16 Centre Leon-Berard Composition pour le traitement des tumeurs neuroendocrines pancreatiques
EP3310375A4 (en) 2015-06-22 2019-02-20 Ampio Pharmaceuticals, Inc. USE OF LOW-MOLECULAR FRACTIONS OF HUMAN SERUMALBUMINE IN THE TREATMENT OF ILLNESSES
CN114099681B (zh) * 2020-12-04 2023-03-10 周清华 Akt/stat3作为免疫检查点抑制剂的靶点的用途
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020003977A1 (en) * 2000-05-11 2002-01-10 Kazunori Kanekura Color image forming apparatus
WO2003093290A2 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US5167649A (en) 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
UA72612C2 (en) * 2000-07-06 2005-03-15 Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
CN1984663A (zh) * 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US8828451B2 (en) * 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
CN101743007B (zh) 2007-07-12 2015-04-08 南佛罗里达大学 具有抗肿瘤活性的akt/pkb抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020003977A1 (en) * 2000-05-11 2002-01-10 Kazunori Kanekura Color image forming apparatus
WO2003093290A2 (en) * 2002-05-06 2003-11-13 Genelabs Technologies, Inc. Nucleoside derivatives for treating hepatitis c virus infection

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GIRARDET, J.-L. et al, "Synthesis and Cytotoxicity of 4-Amino-5-oxopyrido[2,3-d]pyrimidine Nucleosides." Journal of Medicinal Chemistry, 2000, 43(20), 3704-3713 *
RIZKALLA, B. et al, "Pyrido[2,3-d]pyrimidines. 111. Synthesis of Some 8-(beta-DRibofuranosyl) pyrido[2,3-d]pyrimidines Structurally Related to the Antibiotic Sangivamycin." Journal of Organic Chemistry, 1972, 37(25), 3980-3985. *

Also Published As

Publication number Publication date
US8183249B2 (en) 2012-05-22
CA2695330A1 (en) 2009-01-15
WO2009009793A2 (en) 2009-01-15
EP2173352A4 (en) 2011-07-27
JP5568471B2 (ja) 2014-08-06
AU2008274956A1 (en) 2009-01-15
EP2173352B1 (en) 2016-09-07
BRPI0815563A2 (pt) 2015-02-18
KR20100066438A (ko) 2010-06-17
JP2010533206A (ja) 2010-10-21
US20130034598A1 (en) 2013-02-07
CN101743007A (zh) 2010-06-16
WO2009009793A3 (en) 2009-03-26
US20090028855A1 (en) 2009-01-29
KR101618037B1 (ko) 2016-05-04
EP2173352A2 (en) 2010-04-14
CN101743007B (zh) 2015-04-08
CA2695330C (en) 2017-06-13
MX2010000474A (es) 2010-06-23
US9359347B2 (en) 2016-06-07

Similar Documents

Publication Publication Date Title
EP2173352B1 (en) Inhibitors of akt/pkb with anti-tumor activity
EP2646454B1 (en) 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
AU2001273670B2 (en) Pyrido(2,3-d)pyrimidine and pyrimido(4,5-d)pyrimidine nucleosides
KR20260047240A (ko) 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
CN105683166A (zh) 取代的嘧啶Bmi-1抑制剂
US12157755B2 (en) CD73 inhibitor, preparation method therefor and application thereof
EP3833664B1 (en) Smad3 inhibitors
Nassar et al. Design, synthesis of New Pyridine and Pyrimidine Sugar Compounds as Antagonists targeting the ERα via structure-based virtual screening
CA2976067A1 (en) Substituted pyrrolo[2,3-d]pyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors
NZ337844A (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US8426568B2 (en) Rhamnose substituents of SL0101 and therapeutic uses thereof
HK40045137A (en) Smad3 inhibitors
HK1210948A1 (en) Methotrexate adjuvants to reduce toxicity and methods for using the same
HK1156526B (en) Methotrexate adjuvants to reduce toxicity and methods for using the same

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired